BACKGROUND Prompt reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) reduces
C ardiovascular mortality has progressively declined over the last 4 decades, in part due to the prompt delivery of reperfusion therapy to patients with ST-segment elevation myocardial infarction (STEMI) (1) . By rapidly restoring coronary artery patency in STEMI, fibrinolytic therapy reduces infarct size (IS) and mortality. In this regard, the greater reduction in IS with tissue plasminogen activator compared with streptokinase has been associated with improved survival (2) . Compared with fibrinolytic therapy, primary percutaneous coronary intervention (PCI) further reduces IS and improves survival (3, 4) , contributing to improved populationlevel outcomes (1, 5) . However, the benefits of primary PCI are multifactorial, and include restoring epicardial artery patency, which may have salutatory effects in reducing susceptibility to lethal ventricular arrhythmias, preventing expansive left ventricular remodeling, and preserving collateral flow independent of myocardial salvage (the open artery hypothesis) (6) .
Early data suggested a modest correlation between IS and survival after medical therapy in STEMI (7) . The extent to which IS is correlated with outcomes in STEMI has been incompletely characterized in the contemporary primary PCI era. Moreover, whether IS correlates with hospitalization for heart failure (HF) (as would be expected) or reinfarction (which is less intuitive) has not been studied. Given the generally favorable prognosis following primary PCI, most individual studies in which IS has been assessed have been inadequately powered to explore these relationships.
We therefore performed a patient-level pooled analysis from 10 randomized trials of primary PCI in STEMI to examine the relationship between IS assessed within 1 month after reperfusion and subsequent mortality, reinfarction, and hospitalization for HF within 1-year follow-up.
METHODS
The present study represents a collaborative effort between the principal investigators of randomized trials that enrolled patients with STEMI undergoing primary PCI in whom IS was assessed by either cardiac magnetic resonance (CMR) imaging or technetium 
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JACC VOL. 67, NO. 14, 2016 Stone et al. Values are n (%) or median (25th, 75th percentile). *Completed within 37 days of reperfusion and analyzable at the core laboratory, in patients with $6 months of follow-up or earlier death. Thus, some patients in the original reports may not be included in the present study if IS was assessed beyond the 37-day window or if 6-month follow-up was not complete (unless death occurred earlier). †As defined by left anterior descending infarct artery. ‡IS substudy of the main trial. §Patients with both non-ST-segment elevation acute coronary syndromes and STEMI were enrolled in IMMEDIATE. Only STEMI patients are included in this analysis. kTwenty-two patients from LIPSIA-STEMI were also enrolled in LIPSIA-N-ACC (as allowed per protocol), 21 of whom otherwise met the inclusion criteria for this study. These 21 records are only represented once in the current pooled database. Table 1 . A total of Similar relationships held when follow-up time was measured from the date of IS assessment (Online Figure 1) . Table 3 shows the C-statistics for these relationships, which were similar for IS assessment by CMR and SPECT. By multivariable analysis, IS was a strong independent predictor of all-cause mortality, HF hospitalization, and the composite occurrence of all-cause mortality or HF hospitalization, but not for reinfarction ( Table 4 , Online Table 2 ). The NRI for the full versus reduced model was significant for all-cause mortality, HF hospitalization, and mortality or HF hospitalization, but not for reinfarction ( Table 4 , Online Table 2 ). The IDI was significant in this comparison for HF hospitalization and for mortality or HF hospitalization. These findings were similar when only patients without prior myocardial infarction (MI) were analyzed (Online Tables 3 and 4 ). The whiskers of the plot extend from the 10th to 90th percentile. The line inside the box is the median and the top and bottom of the box represent the 1st and 3rd quartiles. 
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A P R I L 1 2 , 2 0 1 6 : 1 6 7 4 -8 3 discrimination for assessment of the risk of subsequent HF hospitalization and death or HF hospitalization. Conversely, IS was not an independent predictor of reinfarction after primary PCI in STEMI.
Previous studies in the fibrinolytic era reported an association between IS as measured by tc-99m sestamibi SPECT and mortality (7, 19) . Notably, however, these analyses were not adjusted for the coex- Prior MI is present in up to 30% of patients with HF hospitalization, which imposes an extraordinary economic burden on the health care system (27) . A B C (A) All-cause mortality, (B) reinfarction, and (C) heart failure hospitalization. A strong graded response between infarct size (IS) and adverse outcomes during 1-year follow-up was present for all-cause mortality and heart failure hospitalization, but not for reinfarction.
IS versus 8.8% in the quartile of patients with the largest IS, a >7-fold increase. By multivariable analysis, every 5% increase in IS contributed to a 20% increase in the relative hazard for all-cause mortality or hospitalization for HF within 1 year after primary PCI.
These data suggest that interventions that reduce IS might favorably affect prognosis in STEMI (assuming no counterbalancing off-target negative effects). In this regard, the greater degree of myocardial salvage and smaller IS with primary PCI as compared with fibrinolytic therapy may in part underlie the survival advantage of the mechanical approach (3, 4) . However, the present study cannot establish causality, and further analyses (which are ongoing) are required to determine whether IS meets the strict criteria to be considered a true surrogate for death and/or HF hospitalization after primary PCI in STEMI (28, 29) .
In contrast to all-cause mortality and HF hospitalization, the relationship between IS and reinfarction was weak, and lost significance when adjusted for measured confounders. As reinfarction is one of the most common causes of death after primary PCI (30, 31) , the present study suggests that reducing reinfarction (e.g., by preventing stent thrombosis) may improve prognosis in STEMI independent of measures taken to enhance myocardial recovery. CI ¼ confidence interval; other abbreviations as in Table 1 .
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